eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
3/2008
vol. 46
 
Share:
Share:
more
 
 
abstract:

REVIEW PAPER
The role of tocilizumab in the treatment of rheumatoid arthritis

Aleksandra Tuchocka
,
Mariusz Puszczewicz

Reumatologia 2008; 46, 3: 140–150
Online publish date: 2008/07/09
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Interleukin 6 (IL-6) is a pleiotropic cytokine displaying multiple biological activities. Dysregulation of IL-6 appears to contribute to both systemic and local rheumatoid arthritis (RA) symptoms. Tocilizumab is a neutralising antibody to suppress IL-6 signalling mediated by both membranous and soluble IL-6-receptor. Clinical efficacy and safety of tocilizumab in RA are discussed in this review. According to data available so far tocilizumab has proved its ability to reduce disease activity, suggesting that IL-6 plays an essential role in the pathogenesis of this chronic autoimmunological inflammatory process.
keywords:

tocilizumab, interleukin 6, rheumatoid arthritis



Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe